D
Danatlas
Research and development of innovative drugs for cancer, inflammation, hematological, and metabolic diseases
About Danatlas
DanAtlas is a biopharmaceutical company based in Beijing, China, focused on the research, development, and commercialization of drug candidates targeting oncology, inflammation, hematological conditions, and metabolic disorders. The company develops a range of therapeutic products, including both small molecules and biologics, and maintains a pipeline that includes first-in-class and globally innovative compounds.
With an internal research and development team and collaborations across the pharmaceutical sector, DanAtlas advances its drug candidates through preclinical and clinical stages. Its portfolio includes treatments for solid tumors, blood cancers, autoimmune diseases, and metabolic syndromes, with several programs in various stages of clinical evaluation.
DanAtlas works to meet international standards for drug development and regulatory compliance, aiming to serve both domestic and global markets. The company combines in-house innovation with external partnerships to support the development and potential commercialization of its therapies.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- China
- Open positions
- None listed
- Dealroom signal
- 22.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Medical Research, Drug Development, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Links
- Website
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Mar 2025 | $21M | $138M | AstraZeneca · HSG · Guofang Innovation · Bayland Capital | ↗ |
| SEEDEquity / VC | Feb 2023 | $0 | — | Sherpa Venture Partners | ↗ |
Growth signals
Latest recorded traffic for Danatlas is 130 monthly website visits, up 116.7% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 EXO BiologicsNovel nanomedicine platform for rare disease therapeutics |
Liège, Belgium | Operational | 17 | $27M | $40M |
 GluBio TherapeuticsEngages in molecular glue-targeted protein degradation drug discovery |
China | Operational | |||
 Vasa TherapeuticsPrecision medicine for heart failure and healthy aging |
Encinitas, United States | Operational | |||
 Latch MedicalA new approach to drug and vaccine delivery |
Dublin, Ireland | Operational | |||
 Convert PharmaceuticalsHypoxia-activated prodrugs targeting treatment-resistant tumors |
Liège, Belgium | Operational | |||
 Nxera Pharma UK | Heptares TherapeuticsDevelops novel, small-molecule drugs for G-protein-coupled receptors |
Great Abington, United Kingdom | Acquired | |||
 MISSION TherapeuticsTherapeutics targeting deubiquitylating enzymes for mitochondrial dysfunction diseases |
Cambridge, United Kingdom | Operational | |||
 BioxodesThrombo-inflammatory therapeutics for intracerebral hemorrhage and stroke |
Marche-en-Famenne, Belgium | Operational |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Sherpa Venture Partners
Series A5 investors entered at this stage
Bayland Capital
AstraZeneca
HSG- GIGuofang Innovation
Pan-Lin Asset Management
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Danatlas on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Danatlas’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.